Radiosensitizer Evaluation
Radiosensitizer Evaluation - Related Videos
04:53
Zebrafish Larvae as a Model to Evaluate Potential Radiosensitizers or Protectors
0 Views •
2022
The zebrafish has recently been exploited as a model to validate potential radiation modifiers. The present protocol describes the detailed steps to use zebrafish embryos for radiation-based screening experiments and some observational approaches to evaluate the effect of different treatments and radiation.
08:32
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
0 Views •
2025
A meticulous and structured approach is given to select resistant and sensitive genes of radiation through the application of a genome-wide CRISPR/Cas9 screen method. This protocol also has the potential to serve as a versatile framework for other research endeavors investigating the mechanisms of resistance to clinically administered chemical drugs.
00:09
Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
0 Views •
2019
The presence of cancer stem cells have been associated with relapse or poor outcomes after radiotherapy. This manuscript describes the methods to study the radiosensitivity of cancer stem cells in lung cancer cell lines.
05:39
Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids
0 Views •
Cited by 1 •
2024
Here, we detail a straightforward live imaging approach for quantifying the sensitivity of patient-derived tumor organoids to ionizing radiation.
08:45
Evaluation of 3D Spheroids for AAV Transduction Studies
0 Views •
2026
Three-dimensional spheroid culture systems improve upon conventional 2D models for AAV gene therapy development. This methodology enables sensitive detection of AAV transduction at low doses, enhanced physiological relevance, and robust long-term monitoring. The platform supports potency assessment, high-throughput screening, and vector optimization across diverse cell lines and AAV serotypes.
FAQs
The paired comparison shows whether the candidate changes the response produced by ionizing radiation rather than merely producing an independent effect. Researchers can assess differences in clonogenic survival, cell viability, DNA damage, apoptosis, or dose enhancement under controlled conditions. This design helps attribute observed changes to the combination and supports more consistent evaluation across candidate treatments.
Different measurements address different parts of the radiation response. Clonogenic survival evaluates the ability of treated cells to retain long-term reproductive capacity, while cell viability provides a broader measure of surviving cells. DNA-damage and apoptosis measurements help examine injury and cell-death responses. Considering these outcomes together can clarify how an agent influences radiation-induced damage and repair.
Dose enhancement indicates whether combining a candidate with radiation produces a stronger response than radiation alone under the tested conditions. It provides a way to compare treatment effects without relying on a single endpoint. When interpreted alongside survival, viability, DNA-damage, and apoptosis measurements, dose-enhancement results can help identify combinations that warrant further preclinical investigation.
Cancer-cell models allow controlled testing of treatment combinations and measurement of defined endpoints, whereas tumor models provide a more relevant setting for examining candidate performance. Results from these systems can complement one another: cell studies help clarify effects on damage, repair, and survival, while tumor-model evaluation supports decisions about which candidates merit further translational or clinical investigation.
A typical evaluation compares radiation alone with radiation combined with the candidate under controlled experimental conditions. Researchers then measure one or more specified outcomes, such as clonogenic survival, cell viability, DNA damage, apoptosis, or dose enhancement. Results are compared between treatment groups to determine whether the combination changes radiation response and merits additional study.
The measurement set should reflect both treatment effect and potential biological explanation. Clonogenic survival and cell viability indicate cellular response, while DNA-damage and apoptosis assays provide information about injury and cell death. Dose-enhancement analysis adds a combination-focused comparison. Using complementary endpoints helps distinguish a stronger radiation response from an isolated change in one measurement.
In cancer research, these studies help prioritize compounds or treatment combinations before translational and clinical investigation. Controlled comparisons identify candidates associated with stronger tumor-directed radiation responses and help clarify how they affect radiation-induced damage and repair. Evaluation in relevant cell and tumor models therefore provides evidence for selecting combinations that may improve tumor control while addressing the goal of limiting normal-tissue exposure.